Logo do repositório
 
Publicação

Vlp-based vaccines as a suitable technology to target trypanosomatid diseases

2021Recensão Acesso aberto
Ver registo simples
dc.contributor.authorQueiroz, Aline Maria Vasconcelos
dc.contributor.authorOliveira, Johny Wysllas de Freitas
dc.contributor.authorMoreno, Cláudia Jassica
dc.contributor.authorGuérin, Diego M.A.
dc.contributor.authorSilva, Marcelo Sousa
dc.contributor.institutionInstituto de Higiene e Medicina Tropical (IHMT)
dc.contributor.institutionGlobal Health and Tropical Medicine (GHTM)
dc.contributor.institutionVector borne diseases and pathogens (VBD)
dc.contributor.pblMDPI - Multidisciplinary Digital Publishing Institute
dc.date.accessioned2021-08-12T23:20:24Z
dc.date.available2021-08-12T23:20:24Z
dc.date.issued2021
dc.descriptionFunding Information: This research was funded by Global Health and Tropical Medicine (Grant number IHMT UID/multi/04413/2013 and Grant number PTDC/CVT-CVT/28908/2017), Funda??o para Ci?ncia e Tecnologia (FCT), Portugal; Grant GIU18/172 Grupos de Investigaci?n de la UPV/EHU, and Grant from CSIC Programa I-COOP+2020 (ICOOPB20503), Spain.A.M.V.Q., J.W.d.F.O., and C.J.M. thanks to the financial support (PhD scholar-ships) provided by CNPq and CAPES, Brazil. M.S.S. thanks to CNPq for the Research Grant (Bolsa de Produtividade em Pesquisa). We are also grateful to Paulo Fanado and Laysa Ohanna for editing this manuscript. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
dc.description.abstractResearch on vaccines against trypanosomatids, a family of protozoa that cause neglected tropical diseases, such as Chagas disease, leishmaniasis, and sleeping sickness, is a current need. Today, according to modern vaccinology, virus-like particle (VLP) technology is involved in many vaccines, including those undergoing studies related to COVID-19. The potential use of VLPs as vaccine adjuvants opens an opportunity for the use of protozoan antigens for the development of vaccines against diseases caused by Trypanosoma cruzi, Leishmania spp., and Trypanosoma brucei. In this context, it is important to consider the evasion mechanisms of these protozoa in the host and the antigens involved in the mechanisms of the parasite–host interaction. Thus, the immunostimulatory properties of VLPs can be part of an important strategy for the development and evaluation of new vaccines. This work aims to highlight the potential of VLPs as vaccine adjuvants for the development of immunity in complex diseases, specifically in the context of tropical diseases caused by trypanosomatids.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent9
dc.format.extent657726
dc.identifier.doi10.3390/vaccines9030220
dc.identifier.otherPURE: 33001665
dc.identifier.otherPURE UUID: c9334c34-f93e-4e37-985d-718df9d2de3d
dc.identifier.otherScopus: 85102682984
dc.identifier.urihttp://hdl.handle.net/10362/122435
dc.identifier.urlhttps://www.scopus.com/pages/publications/85102682984
dc.language.isoeng
dc.peerreviewedyes
dc.subjectAfrican try-panosomiasis
dc.subjectChagas disease
dc.subjectLeishmaniasis
dc.subjectTrypanosomatids
dc.subjectVaccine
dc.subjectVirus-like particles
dc.subjectImmunology
dc.subjectPharmacology
dc.subjectDrug Discovery
dc.subjectInfectious Diseases
dc.subjectPharmacology (medical)
dc.subjectSDG 3 - Good Health and Well-being
dc.subjectSDG 17 - Partnerships for the Goals
dc.titleVlp-based vaccines as a suitable technology to target trypanosomatid diseasesen
dc.typereview
degois.publication.firstPage1
degois.publication.issue3
degois.publication.lastPage9
degois.publication.titleVaccines
degois.publication.volume9
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
vaccines_09_00220.pdf
Tamanho:
642.31 KB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

IHMT: MM - Artigos em revista internacional com arbitragem científica